The Sinopharm-backed antimicrobial drug developer received $107m in a Legend Capital-led round that took its overall funding to $255m.

Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, has led a RMB700m ($107 million) series E round for China-based antimicrobial therapeutics developer MicuRx Pharmaceuticals, DealStreetAsia reported on Monday. China Merchants Group subsidiary China Merchants Securities also took part in the round, as did Korea Investment Partners, Yingke PE, Founder H Fund, Zhongtai…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Robert Lavine

Robert Lavine is special features editor for Global Venturing.